Ana-Maria Vlădăreanu *, A. Coliță **, Diana Câșleanu ***, Mirela Lăcătuș ****
* Dr. Ana-Maria Vlădăreanu, medic primar hematologie clinică și hemobiologie, șef lucrări UMF Carol Davila•, Cli11ica de Hematologie Co/Jea, Bucure§li
** Dr. Andrei Coliță, medic specialist hematologie, asistent universitar UMF “Carol Davila”, Clinica de Hematologie Colțea, București
*** Dr. Diana Ca§lea111,, medic specialist hemato/ogie clillica, Clillica de Hematologie Colțea, București
**** Mirela Lăcătuș, medic rezident
Abstract
Conventional chemotherapy for patients with low- and high-grade non-Hodgin’s lymphoma allows an overall survival rate of 30 – 40%. The disease is often refractory to initial chemotherapy or
develops relapses. These patients have a poor prognosis and it is rarely obtained a new remission
using standard chemotherapy. As concerns indolent non-Hodgkin’s lymphoma, overall survival slope is continuosly descendent, different from that in other types of NHL which is flat (4). Attempts to increase agents’ doses in chemotherapy regimens haven’t resulted in a significant extension of overall survival. For these reasons, it was considered that enhancing chemotherapy doses until the myeloablative level (which may require haematological support using a progenitor cell infusion) might cause in patients who are not responding to conventional chemotherapy malign clone destruction. In 1978, the scientists from Bethesda National Cancer Institute reported first positive results in the treatment of refractory non-Hodgkin’s lymphomas using high-dose therapy followed by auto bone marrow transplant.